US · Healthcare · Biotechnology
EPS came in at -0.12 against a street estimate of -0.14 — a beat of 14.3%.
Analysts rate Shattuck Labs Inc a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $14.67.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 9.83% |
| Adage Capital Partners Gp LLC | 8.09% |
| Redmile Group, LLC | 6.87% |
| Orbimed Advisors LLC | 6.28% |
| Prosight Management, LP | 5.94% |
| NEXTBio Capital Management LP | 3.71% |
| Deep Track Capital, LP | 3.69% |
| Vanguard Capital Management, LLC | 2.27% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 SHATTUCK LABS, INC. - FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash position: $63.3 million in cash and cash equivalent | 2026-08-11 |
| Results announced · Q3 2026 SHATTUCK LABS, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Cash and short-term investments: $208.3 million as of June 30, 2026 (up from $50.5 | 2026-08-11 |
| Material agreement · Q2 2026 SHATTUCK LABS, INC. (STTK) — 8-K SUMMARY HEADLINE NUMBERS • Company completed underwritten public offering on June 9, 2026 • Offered 10,879,376 shar | 2026-06-11 |
| Reg FD disclosure · Q2 2026 SHATTUCK LABS, INC. - 8-K SUMMARY (June 8-9, 2026) HEADLINE NUMBERS • Warrant exercises: 50.6 million outstanding common stock warrants exercised, r | 2026-06-09 |
| Board / officer change · Q2 2026 SHATTUCK LABS, INC. (STTK) - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 28, 2026 • 75,581,787 shares of common stock outstanding as of A | 2026-06-02 |
| Quarterly report · Q1 2026 SHATTUCK LABS, INC. – Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $90.4 million in cash and cash equivalents as of March 31, 2026 (u | 2026-05-07 |
| Proxy statement · Q2 2026 SHATTUCK LABS, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class III director nominees (Dr. Taylor | 2026-04-08 |
| Annual report FY2025 SHATTUCK LABS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Shattuck Labs, Inc. (NASDAQ: STTK), clinical-stage biotechnology | 2026-03-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Shattuck Labs Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.